GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera AG (XTER:B8FK) » Definitions » Institutional Ownership

Biofrontera AG (XTER:B8FK) Institutional Ownership : 0.05% (As of May. 26, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Biofrontera AG Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biofrontera AG's institutional ownership is 0.05%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biofrontera AG's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biofrontera AG's Float Percentage Of Total Shares Outstanding is 0.00%.


Biofrontera AG Institutional Ownership Historical Data

The historical data trend for Biofrontera AG's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera AG Institutional Ownership Chart

Biofrontera AG Historical Data

The historical data trend for Biofrontera AG can be seen below:

2022-08-31 2022-09-30 2022-10-31 2022-11-30 2022-12-31 2023-01-31 2023-02-28 2023-03-31 2023-04-30 2023-05-31
Institutional Ownership 0.40 0.31 0.11 0.11 0.10 0.10 0.10 0.10 0.10 0.05

Biofrontera AG Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Biofrontera AG (XTER:B8FK) Business Description

Traded in Other Exchanges
Address
Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

Biofrontera AG (XTER:B8FK) Headlines

No Headlines